Yingjiexin Medical announced an RMB 200 million Series B on 2 November 2026, led by a fund affiliated with CICC Capital. Zhuhai Technology Industry Group, Co Stone Capital, Qiming Venture Partners, Houxin Health Investment and Yingyue Fund joined, while GRC SinoGreen Capital reinvested. The Shanghai company develops precision drug delivery devices, including disposable and reusable injection pens and automatic injectors for biologic medicines. Yingjiexin said the proceeds will expand production and delivery, accelerate new products, and support overseas registration and sales. The amount is current equity funding, not cumulative capital, a grant or a fundraising target.
Yingjiexin Medical raises RMB 200m Series B
CICC Capital affiliated fund leads drug delivery device financing

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


